AU2003256068A1 - Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases - Google Patents

Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases Download PDF

Info

Publication number
AU2003256068A1
AU2003256068A1 AU2003256068A AU2003256068A AU2003256068A1 AU 2003256068 A1 AU2003256068 A1 AU 2003256068A1 AU 2003256068 A AU2003256068 A AU 2003256068A AU 2003256068 A AU2003256068 A AU 2003256068A AU 2003256068 A1 AU2003256068 A1 AU 2003256068A1
Authority
AU
Australia
Prior art keywords
hydrogen atom
hydroxy
macrolide compound
alkyl
ophthalmic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003256068A
Other languages
English (en)
Inventor
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo Pharmaceuticals Inc
Original Assignee
Sucampo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Pharmaceuticals Inc filed Critical Sucampo Pharmaceuticals Inc
Publication of AU2003256068A1 publication Critical patent/AU2003256068A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
AU2003256068A 2002-08-09 2003-08-08 Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases Abandoned AU2003256068A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40206102P 2002-08-09 2002-08-09
US60/402,061 2002-08-09
PCT/JP2003/010105 WO2004014373A1 (en) 2002-08-09 2003-08-08 Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases

Publications (1)

Publication Number Publication Date
AU2003256068A1 true AU2003256068A1 (en) 2004-02-25

Family

ID=31715781

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003256068A Abandoned AU2003256068A1 (en) 2002-08-09 2003-08-08 Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases

Country Status (10)

Country Link
US (1) US20050239813A1 (enExample)
EP (1) EP1536793A1 (enExample)
JP (2) JP2005536531A (enExample)
KR (1) KR20050054913A (enExample)
CN (1) CN1674896A (enExample)
AU (1) AU2003256068A1 (enExample)
BR (1) BR0313425A (enExample)
CA (1) CA2495103A1 (enExample)
MX (1) MXPA05001575A (enExample)
WO (1) WO2004014373A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040019034A (ko) * 2001-07-06 2004-03-04 수캄포 아게 인터루킨 2 억제제 및 항미생물제를 포함하는 국소 투여용조성물
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
BRPI0607606B1 (pt) 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. Formulação líquida
EP1904056B1 (en) 2005-07-18 2009-04-29 Minu, L.L.C. Use of a macrolide to restore corneal sensation
CN1965825B (zh) * 2005-11-17 2011-07-06 洪晶 一种治疗眼部免疫性疾病及抑制增殖、新生血管的眼表用药
CN101605529B (zh) 2006-02-09 2013-03-13 参天制药株式会社 稳定制剂及它们的制备和使用方法
BRPI0709016A2 (pt) 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
KR100891313B1 (ko) 2007-08-17 2009-03-31 (주) 제노텍 담체로 작용하는 흡착성 수지의 제공에 의한 트리사이클로화합물의 생산 및 추출 방법
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
KR101632042B1 (ko) * 2014-06-30 2016-06-21 주식회사 인트론바이오테크놀로지 Fk506 유도체를 함유하는 크립토코쿠스 속 곰팡이 및 칸디다 속 곰팡이에 의한 진균 감염을 치료하기 위한 약제학적 조성물 및 그의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU635286B2 (en) * 1989-07-05 1993-03-18 Astellas Pharma Inc. Aqueous liquid composition for external use
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
JP3158437B2 (ja) * 1991-04-26 2001-04-23 藤沢薬品工業株式会社 眼疾患に対するマクロライド化合物の使用
US7063857B1 (en) * 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
WO2000066122A1 (en) * 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
KR20040019034A (ko) * 2001-07-06 2004-03-04 수캄포 아게 인터루킨 2 억제제 및 항미생물제를 포함하는 국소 투여용조성물
US20050070468A1 (en) * 2001-11-21 2005-03-31 Sucampo Ag Use of fk506 and analogues for treating allergic diseases

Also Published As

Publication number Publication date
EP1536793A1 (en) 2005-06-08
KR20050054913A (ko) 2005-06-10
JP2005536531A (ja) 2005-12-02
MXPA05001575A (es) 2005-08-19
CA2495103A1 (en) 2004-02-19
WO2004014373A1 (en) 2004-02-19
US20050239813A1 (en) 2005-10-27
BR0313425A (pt) 2005-07-05
JP2011012071A (ja) 2011-01-20
CN1674896A (zh) 2005-09-28

Similar Documents

Publication Publication Date Title
US6872383B2 (en) Use of macrolide compounds for the treatment of dry eye
US7033604B2 (en) Composition for topical administration
JP2011012071A (ja) アレルギー性疾患を処置する為のｆｋ５０６誘導体を含む医薬組成物及びその使用
JP5036934B2 (ja) ドライアイ処置の為のマクロライド化合物の使用
US6864232B1 (en) Agent for treating visual cell function disorder
US20020187998A1 (en) Local ophthalmic agent for treatment of ocular inflammation
US20040198763A1 (en) Method of treating dry eye with a macrolide compound
US20050070468A1 (en) Use of fk506 and analogues for treating allergic diseases
KR20010099928A (ko) 시세포 기능 질환 치료제
AU2002314558A1 (en) Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
AU2002248014A1 (en) Agent for topical ophthalmic treatment of ocular inflammatory diseases

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period